Loading
Adding the AKT inhibitor capivasertib to fulvestrant doubled the time to progression in advanced hormone receptor-positive breast cancer after aromatase inhibitor failure, with the largest gain in tumours with PIK3CA, AKT1 or PTEN alterations.
Phase 3 placebo-controlled trial of 708 patients with hormone receptor-positive, HER2-negative advanced breast cancer that had relapsed or progressed on an aromatase inhibitor, about 70 percent after a CDK4/6 inhibitor, randomised to capivasertib or placebo with fulvestrant.
Median progression-free survival was 7.2 versus 3.6 months overall (hazard ratio 0.60) and 7.3 versus 3.1 months in the AKT pathway-altered population (hazard ratio 0.50). Diarrhoea, rash and hyperglycaemia were the main toxicities.
Capivasertib-fulvestrant is a standard option for tumours with PIK3CA, AKT1 or PTEN alterations after a CDK4/6 inhibitor, adding a second targeted pathway to endocrine therapy.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, New England Journal of Medicine.
Shares CAPItello-291, Capivasertib.
Shares Capivasertib, HR-positive metastatic breast cancer after CDK4/6 inhibitors.
Shares Capivasertib, HR-positive metastatic breast cancer after CDK4/6 inhibitors.
Shares Capivasertib, HR-positive metastatic breast cancer after CDK4/6 inhibitors.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, New England Journal of Medicine.
Shares CAPItello-291, Capivasertib.